Articles, Issue 1/2022

Modern Reading of Crohn’s Disease -Clinical and Immunological Features and new Therapeutic Possibilities

Posted on by admin

H. Burnusuzov


Abstract

Crohn’s disease (CD) is one of the rare diseases in the general pediatric practice. The pathogenesis of the condition, albeit not completely understood, is traditionally attributed to the disorders of innate immunity, but contemporary studies yet place it on the borderline between autoinflammatory diseases,
primary immune deficiencies and autoimmune conditions. This review focuses on the immunological mechanisms that are responsible for the onset of the disease, in particular the role of some genetic factors, T cells and cytokine signaling. Besides the classical medications, some new options for targeted therapy in CD are also described.
Key words: Crohn’s disease, immunology, targeted therapy

To access this content, you must purchase Годишен абонамент.

Bibliography

  1. Гроздева К, Лисички К. Автовъзпалителните заболявания през погледа на детския гастроентеролог. Практическа педиатрия, 5,  2020, стр. 18-21.
  2. Шентова Р, Пантелеева Е. Възпалителни чревни заболявания с много ранно начало. Практическа педиатрия|1-2/2021, стр. 6-8.
  3. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007;14:10–22.
  4. Ting JP, Kastner DL, Hoffman HM. CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol. 2006;6:183–95.
  5. Murthy A, Li Y, Peng I, et al. A Crohn’s disease variant in Atg16l1 enhances its degradation by caspase 3. Nature 2014;506:456–62.
  6. Fiocchi C. Inflammatory bowel disease pathogenesis: where are we? J Gastroenterol Hepatol 2015;30:12–18.
  7. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 2009;104:2100–9.
  8. Mahid SS, Mulhall AM, Gholson RD, et al. Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis 2008;14:960–7.
  9. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011;140:1704–12.
  10. Шентова Р. Възпалителни чревни заболявания в детската възраст. В: „Спешна педиатрия- Гастроентерология“, п/р Т. Шмилев, Лакс бук, Пловдив, 2014, стр. 315- 327.
  11. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006;25:309–18.
  12. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006;116:1310–16.
  13. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45Rbhi CD4+ T cells. Immunity 1994;1:553–62.
  14. Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006;12:9–15.
  15. Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16:233–42.
  16. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL- 17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693–700.
  17. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med 2004;351:2069–79.
  18. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012;367:1519–28.
  19. Интернет страница на Европейската агенция за лекарствата, ЕМА. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000311-pip03-11-m06; посетено на  30.11.2021г.
  20. McGovern DP, Kugathasan S, Cho JH. Genetics of Inflammatory Bowel Diseases. Gastroenterology 2015;149:1163–76, e2.
  21. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001 May 31;411(6837):603-6. doi: 10.1038/35079114. PMID: 11385577.
  22. Peyrin-Biroulet L, Chamaillard M. NOD2 and defensins: translating innate to adaptive immunity in Crohn’s disease. J Endotoxin Res. 2007;13(3):135-9. doi: 10.1177/0968051907080429. PMID: 17621555.
  23. Murthy A, Li Y, Peng I, et al. A Crohn’s disease variant in Atg16l1 enhances its degradation by caspase 3. Nature 2014;506:456–62.
  24. Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an intracellular pathogen induced by a Crohn’s disease associated ATG16L1 variant. PLoS ONE 2008;3:e3391.
  25. Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci USA 2011;108:9560–5.
  26. Erickson AR, Cantarel BL, Lamendella R, et al. Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn’s disease. PLoS ONE 2012;7:e49138.
  27. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002;8:244–50.
  28. Шентова Р, Янева П, Пантелеева Е, Михова А, Хаджийски П, Желев Х. Роля на фекалния калпротектин при проследяването на деца с хронични възпалителни чревни заболявания. Педиатрия, том LVI, 2/2016 година, стр.6-8.
  29. Шентова Р, Великова Ц, Желев Х, Пантелеева Е, Янева П, Михова А, Хаджийски П. Роля на фекалния калпротектин в диагностиката на деца с хронични възпалителни чревни заболявания. Педиатрия, том LV, 4/2015 година, стр.25-27.
  30. Шентова Р. Нови маркери в диагностиката на деца с хронични възпалителни чревни заболявания. Практическа педиатрия,7, 2015г., стр. 8-10.
  31. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006;101:2410–22.
  32. Тодорова Е, Юзеир Т. Лабораторни методи за изследване на имунния отговор- изследване на автоантитела, в „Клинична имунология“, п/р. Е. Наумова, Централна медицинска библиотека, София, 2021; стр. 297.
  33. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641–57.
  34. Интернет страница на Европейската агенция за лекарствата, ЕМА.   https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio; посетено на  30.11.2021г.
  35. Интернет страница на Европейската агенция за лекарствата, ЕМА.  https://www.ema.europa.eu/en/medicines/human/EPAR/natalizumab-elan-pharma посетено на  30.11.2021г.
  36. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–95.
  37. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 2009;29:2727–37.

Address for correspondence:

Department of Pediatrics and Medical Genetics
Medical University – Plovdiv
15A, “Vasil Aprilov”, Blvd.
4000, Plovdiv
Bulgaria
e-mail: hasan.burnusuzov@mu-plovdiv.bg
hassan_md@abv.bg